Carl Zeiss Meditec Stock Today

CZMWF Stock  USD 54.21  2.21  4.25%   

Performance

Very Weak

 
Weak
 
Strong

Odds Of Distress

Low

 
High
 
Low
Carl Zeiss is trading at 54.21 as of the 16th of February 2025. This is a 4.25 percent increase since the beginning of the trading day. The stock's lowest day price was 54.21. Carl Zeiss has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 17th of January 2025 and ending today, the 16th of February 2025. Click here to learn more.
Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, the United States, Asia, and internationally. The company was founded in 1846 and is headquartered in Jena, Germany. Carl Zeiss operates under Medical Instruments Supplies classification in the United States and is traded on OTC Exchange. The company has 89.44 M outstanding shares. More on Carl Zeiss Meditec

Moving against Carl Pink Sheet

  0.63ANET Arista Networks Earnings Call This WeekPairCorr
  0.42COHG Cheetah Oil GasPairCorr
Follow Valuation Odds of Bankruptcy
Check how we calculate scores

Carl Pink Sheet Highlights

Business ConcentrationMedical Instruments & Supplies, Healthcare (View all Sectors)
Carl Zeiss Meditec [CZMWF] is a Pink Sheet which is traded between brokers over the counter. The company currently falls under 'Large-Cap' category with a current market capitalization of 12.53 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Carl Zeiss's market, we take the total number of its shares issued and multiply it by Carl Zeiss's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Carl Zeiss Meditec classifies itself under Healthcare sector and is part of Medical Instruments & Supplies industry. The entity has 89.44 M outstanding shares. Carl Zeiss Meditec has accumulated about 8.4 M in cash with 188.2 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.09.
Check Carl Zeiss Probability Of Bankruptcy
Ownership Allocation
Carl Zeiss holds a total of 89.44 Million outstanding shares. Carl Zeiss Meditec retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Carl Ownership Details

Carl Zeiss Meditec Risk Profiles

Carl Stock Against Markets

Be your own money manager

Our tools can tell you how much better you can do entering a position in Carl Zeiss without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Technical Analysis Now

   

Technical Analysis

Check basic technical indicators and analysis based on most latest market data
All  Next Launch Module

Carl Zeiss Corporate Management

Other Information on Investing in Carl Pink Sheet

Carl Zeiss financial ratios help investors to determine whether Carl Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Carl with respect to the benefits of owning Carl Zeiss security.